Treatment Clinical Trials for Intraocular Melanoma

Clinical trials are research studies that involve people. The clinical trials on this list are for intraocular melanoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-23 of 23
  • Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

    To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
    Location: 17 locations

  • A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

    IMCgp100-102 is a Phase I study of the weekly intra-patient escalation dose regimen with IMCgp100 as a single agent in patients with metastatic uveal melanoma (mUM). According to this regimen, all patients in the trial will receive 2 weekly doses of IMCgp100 at a dose level below the identified weekly recommended Phase II dose (RP2D-QW) and then a dose escalation will commence at the third weekly dose at C1D15. The Phase I testing of the intra-patient escalation dosing regimen is designed to achieve a higher exposure and maximal plasma concentration of IMCgp100 after doses at Cycle 1 Day 15 (C1D15) and thereafter .
    Location: 8 locations

  • A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

    This is the first-in-human study of the safety of increasing dose levels of AEB1102 in patients with advanced cancers. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and tumor growth.
    Location: 7 locations

  • Ulixertinib in Treating Patients with Stage IV Uveal Melanoma

    This phase II trial studies the side effects of ulixertinib and how well it works in treating patients with stage IV uveal melanoma. Ulixertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

    This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
    Location: 4 locations

  • Study in Subjects With Small to Medium Primary Choroidal Melanoma

    The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
    Location: 3 locations

  • Selumetinib Sulfate in Treating Patients with Uveal Melanoma or GNAQ / GNA11 Mutated Melanoma That Is Metastatic or Cannot Be Removed by Surgery

    This phase Ib trial studies the side effects and best dose of selumetinib sulfate in treating patients with uveal melanoma or GNAQ / GNA11 mutated melanoma that has spread from the primary site to other places in the body or cannot be removed by surgery. Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

    This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.
    Location: 2 locations

  • Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

    Reports to date show limited efficacy of immunotherapy for uveal melanoma. Recent experimental and clinical evidence suggests synergy between radiation therapy and immunotherapy. The investigators will explore this synergy with a feasibility study of 18 patients with uveal melanoma and hepatic metastases who will receive SirSpheres Yttrium-90 selective internal hepatic radiation followed by immunotherapy with the combination of ipilimumab and nivolumab.
    Location: 2 locations

  • Ipilimumab and Nivolumab with Immunoembolization in Treating Participants with Metastatic Uveal Melanoma in the Liver

    This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating participants with uveal melanoma that has spread to the liver. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating participants with uveal melanoma.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • A Study of PLX2853 in Advanced Malignancies.

    The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Autologous CD8+ SLC45A2-Specific T Lymphocytes with Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Participants with Metastatic Uveal Melanoma

    This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab, and to see how well they work in treating participants with uveal melanoma that has spread to other places in the body. To make specialized CD8+ T cells, researchers separate out T cells collected from participant blood and treat them so they are able to target melanoma cells. The blood cells are then given back to the participant. This is known as "adoptive T cell transfer" or "adoptive T cell therapy". Drugs used in chemotherapy, such as cyclophosphamide, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Biological therapies, such as aldesleukin, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving autologous CD8+ SLC45A2-specific T lymphocytes together with cyclophosphamide, aldesleukin, and ipilimumab may work better in treating participants with metastatic uveal melanoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Intravenous and Intrathecal Nivolumab in Treating Patients with Leptomeningeal Disease

    This phase I / Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML / MDS or Metastatic Uveal Melanoma

    The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are modified to recognize and target the PRAME tumor marker on cancer cells.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

    This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
    Location: Columbia University / Herbert Irving Cancer Center, New York, New York

  • Nivolumab with or without Ipilimumab or Relatlimab before Surgery in Treating Patients with Stage IIIB-IV Melanoma That Can Be Removed by Surgery

    This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, and relatlimab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab alone or in combination with ipilimumab or relatlimab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: M D Anderson Cancer Center, Houston, Texas

  • 6 Melanoma Helper Peptide Vaccine and Pembrolizumab in Treating Patients with Unresectable Stage IIIB, IIIC or IV Melanoma

    This phase I / II trial studies the side effects and how well the 6 melanoma helper peptide vaccine and pembrolizumab work in treating patients with stage IIIB, IIIC or IV melanoma that cannot be removed by surgery. Vaccines made from peptides, such as the 6 melanoma helper peptide vaccine, may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving the 6 melanoma helper peptide vaccine and pembrolizumab may work better in treating patients with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • 6MHP Vaccine and Ipilimumab in Treating Patients with Stage IIA-IV Melanoma

    This phase I / II trial studies the side effects of 6 melanoma helper peptide vaccine (6MHP) and ipilimumab and to see how well they work in treating patients with stage IIA-IV melanoma. Vaccines made from peptides, such as 6MHP vaccine, may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving 6MHP vaccine and ipilimumab may work better in treating patients with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Dabrafenib Mesylate , Trametinib, and 6 Melanoma Helper Peptide Vaccine in Treating Participants with Stage IIIB-IV Melanoma

    This trial studies the side effects and how well dabrafenib mesylate, trametinib, and 6 melanoma helper peptide vaccine work in treating participants with stage IIIB-IV melanoma. Dabrafenib mesylate and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines, such as 6 melanoma helper peptide vaccine, made from peptides derived from melanoma proteins, may help the body build an effective immune response to kill tumor cells that express melanoma-specific antigens. Giving dabrafenib, trametinib, and 6 melanoma helper peptide vaccine may work better in treating participants with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia

  • Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

    This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma

    This randomized phase II trial studies how well therapeutic tumor infiltrating lymphocytes and high-dose aldesleukin with or without autologous dendritic cells work in treating patients with melanoma that has spread to other areas of the body. Vaccines made from a person's tumor cells and special blood cells (dendritic cells) may help the body build an effective immune response to kill tumor cells. Aldesleukin may stimulate the white blood cells to kill tumor cells. It is not yet known whether therapeutic tumor infiltrating lymphocytes and high-dose aldesleukin are more effective when given together with or without dendritic cells in shrinking or slowing the growth of melanoma. The clinical benefits of receiving tumor infiltrating lymphocytes (TIL) in combination with the B-Raf proto-oncogene, serine / threonine kinase (BRAF) inhibitor will be studied, in patients who have progressive disease (PD) with using the BRAF inhibitor prior to TIL treatment. Leptomeningeal disease (LMD) is unfortunately a common development in patients with melanoma, with an extremely poor prognosis, translating into an overall survival of only weeks. With the novel approach of combining intrathecal TILs and intrathecal interleukin (IL)-2, researchers hope to induce long term disease stabilization or remission of LMD.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, and Aldesleukin in Treating Participants with Metastatic Uveal Melanoma

    This phase II trial studies how well cyclophosphamide, fludarabine, tumor infiltrating lymphocytes, and aldesleukin work in treating participants with uveal melanoma that has spread to other places in the body. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Tumor infiltrating lymphocytes may be an effective treatment for uveal melanoma. Aldesleukin may stimulate white blood cells to kill uveal melanoma cells. Giving cyclophosphamide, fludarabine, tumor infiltrating lymphocytes, and aldesleukin may kill more tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients with Uveal Melanoma

    This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania